Off-the-Shelf Prostate Stem Cell Antigen–Directed Chimeric Antigen Receptor Natural Killer Cell Therapy to Treat Pancreatic Cancer

Pre-conditioning modifies the TME to enhance solid tumor CAR T cell efficacy and endogenous protective immunity

(2021) John P. Murad et al.   MOLECULAR THERAPY

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

(2020) Enli Liu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients

(2019) Lin Xiao et al.   MOLECULAR THERAPY

Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial

(2018) Gregory L. Beatty et al.   GASTROENTEROLOGY

The Potential of CAR T Cell Therapy in Pancreatic Cancer

(2018) Mehmet Akce et al.   Frontiers in Immunology

PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells

(2017) Xinru Wei et al.   OncoImmunology

Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer

(2017) Saul J. Priceman et al.   OncoImmunology

Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma

(2016) Avery D. Posey et al.   IMMUNITY

Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia

(2016) Paulina J. Paszkiewicz et al.   JOURNAL OF CLINICAL INVESTIGATION

Toward a Shared Vision for Cancer Genomic Data

(2016) Robert L. Grossman et al.   NEW ENGLAND JOURNAL OF MEDICINE

CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells

(2015) Jianfeng Han et al.   Scientific Reports

Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity

(2014) P. S. Adusumilli et al.   Science Translational Medicine

CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma

(2013) J Chu et al.   LEUKEMIA

The Cancer Genome Atlas Pan-Cancer analysis project

(2013) John N Weinstein et al.   NATURE GENETICS

Location and cellular stages of natural killer cell development

(2013) Jianhua Yu et al.   TRENDS IN IMMUNOLOGY

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells

(2011) X. Wang et al.   BLOOD

Epidermal Growth Factor Receptor in Pancreatic Cancer

(2011) Melissa Oliveira-Cunha et al.   Cancers

NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects

(2010) J. A. Olson et al.   BLOOD

Clinical Significance of Prostate Stem Cell Antigen Expression in Non-small Cell Lung Cancer

(2010) Takeshi Kawaguchi et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

FKBP51 Affects Cancer Cell Response to Chemotherapy by Negatively Regulating Akt

(2009) Huadong Pei et al.   CANCER CELL

Human natural killer cells

(2008) M. A. Caligiuri   BLOOD